07:56 AM EDT, 10/27/2025 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said it received positive preclinical data from three studies with mice for its potential obesity drug NMRA-215.

The drug showed weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with semaglutide, the company said.

Chief Executive and Chairman Paul Berns said the data "reinforce our conviction that NMRA-215 may be an effective, next-generation, oral treatment for obesity."

Shares of the company were up 1.1% in recent premarket activity.